The FINANCIAL — Amgen on January 9 announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc.
This is a continuation of Amgen’s long-term relationship with DaVita that is focused on serving dialysis patients, according to Amgen.
Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN (epoetin alfa) and Aranesp (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita’s and its affiliates’ requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico. The percentage varies during the term of the new agreement from Jan. 6, 2017, through Dec. 31, 2022, but in each year is at least 90 percent. The new agreement will replace the Sourcing and Supply Agreement dated Nov. 15, 2011, between Amgen and DaVita that would have expired on Dec. 31, 2018.